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Purpose: We report the case of a 33-year-old male who presented with unilateral central serous retinopathy three
days after the injection of a COVID-19 vaccine.
Observations: A 33-year-old healthy Hispanic male referred to the ophthalmology service due to blurry vision and
metamorphopsia in the right eye without any flashes, floaters, eye redness or pain. The patient reported that 69
hours prior to presentation he received the first dose of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vac
cine. He denied any past ocular history or pertinent medical history. He does not take any medicines and denies
stressful factors in his life. The clinical examination and imaging tests were consistent with central serous reti
nopathy that resolved in three months.
Conclusions and importance: This is the first report of an ocular complication potentially associated with a COVID19 vaccination. Our case contributes information of a side effect potentially related to this new vaccine.

1. Introduction

2. Case report

Since the first report of the novel coronavirus SARS-CoV-2 in China
in December 2019, COVID-19 has been responsible for more than three
million deaths worldwide. The ongoing outbreak of COVID-19 has been
declared by the World Health Organization as a public health emergency
and a vaccine to control the situation was anxiously expected. Vaccine
development occurred in less than one year and thus, long-term data on
side effects are still developing.
The most common ocular manifestation of COVID-19 is hyperemia or
conjunctival “congestion.“1,2 In addition, reports of central retinal vein
occlusion,3 toxic shock syndrome4 and hemorrhages with microinfarcts
have been described in COVID-19 patients.5 To the best of our knowl
edge, no intraocular side effects have been reported from any of the
COVID-19 vaccinations (a case of Bell’s Palsy was described in a patient
who received the Moderna mRNA COVID-19 vaccine).6
We present a unique case of a healthy Hispanic male who presented
with unilateral central serous retinopathy (CSR), temporally related to
the administration of a COVID-19 vaccine.

A 33-year-old healthy Hispanic male was referred for ophthalmo
logical evaluation due to blurry vision and metamorphopsia in his right
eye. He denied flashes, floaters, ocular pain or redness. He did not have
any visual symptoms in his left eye.
Past ocular history was negative except for mild hyperopic refractive
error. Past medical history was only significant for hip surgery post
traumatic injury six years prior to presentation. He denied use of any
medications including any remote history of corticosteroids. 69 hours
before presentation he received the Pfizer-BioNTech mRNA COVID-19
vaccine, after which, he reported soreness at the injection site and fa
tigue for 24 hours. Since the inception of the pandemic, the patient has
experienced no COVID-19 symptoms and had a negative PCR result in
November 2020.
On exam, his best corrected visual acuity (BCVA) was 20/63 and 20/
25 in his right and left eye, respectively. Pupils were equally round and
reactive to light and accommodation. Intraocular pressure was 10
mmHg in both eyes.
Anterior segment exam was within normal limits. Dilated fundus
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Fig. 1. Clinical evaluation of a patient with unilateral central serous retinopathy. Right eye (left column) and left eye (right column) are shown. Fundus photography
of the posterior pole (A) of the right eye shows an inferotemporal parafoveal depigmented lesion. The left eye fundus was normal. Optical coherence tomography (B)
of the right eye shows a serous detachment of the neurosensory retina in the central macula.

Fig. 2. Vascular examinations of the effected eye of a patient with unilateral central serous retinopathy. (A) Fluorescein angiography from early (left) to late (right)
angiogram phases show the classic expansile dot just inferotemporal to the fovea. Optical coherence tomography angiography (B) of the right eye is unremarkable in
the superficial (left) and deep (second from left) capillary plexuses and avascular segments (second from right) but shows generally attenuated flow signal that
colocalized to the area of serous retinal detachment and foci of increased flow signal at the level of the choriocapillaris (right).

examination was normal in the left eye but revealed loss of foveal reflex
and swollen appearance of the macula in the right eye. No hemorrhages
or vascular abnormalities were noted (Fig. 1A).
Optical coherence tomography (OCT) of the right eye showed a
macular serous detachment of the neurosensory retina (Fig. 1B) with a
central foveal thickness (CFT) of 457 μm. OCT of the left eye was un
remarkable. On fluorescein angiography (FA), a single point of leakage
was noted following the classical ink-blot pattern, with progressive
expansion of hyperfluorescence emanating from a single point (Fig. 2A).
Consistent with previous reports of CSR,7–9 OCT angiography (OCTA)
showed generally attenuated flow signal in the choriocapillaris that
colocalized to the area of serous retinal detachment and foci of increased
flow signal (Fig. 2B).
After the initial evaluation, the patient was prescribed spi
ronolactone 50mg daily and was evaluated two and three months later.

At the two-month visit, BCVA improved to 20/40 and CFT decreased to
325 μm. At the three-month visit, BCVA improved to 20/20, CFT
decreased to 211 μm, OCT showed complete resolution of subretinal
fluid, and the patient was asymptomatic.
3. Discussion
We present a case of acute unilateral CSR that developed shortly after
immunization with the Pfizer-BioNTech mRNA COVID-19 vaccine. To
the best of our knowledge, this is the first report of an intraocular
complication associated with COVID-19 vaccination.
We believe it is prudent to consider the immunization as a potential
contributor to disease, given 1) the temporal association between im
munization and symptom onset, 2) the relatively low incidence of CSR
(9.9 per 100,000 individuals)10 and 3) our case’s absence of classical risk
2
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factors for CSR development (including a history of exogenous steroid
use, recent stressful social history, and type-A personality).11 While no
cases of mRNA COVID-19 vaccine associated CSR have been reported to
date, CSR has been associated with vaccinations against influenza, yel
low fever, anthrax and smallpox.12–15 Still, these cases are rare. In fact, a
search of the terms “central serous”, “central serous retinopathy”,
“central serous chorioretinopathy” and “CSR” across all vaccine prod
ucts by all vaccine manufacturers yielded no results from 1990 to date
using the U.S. Centers for Disease Control and Prevention’s Vaccine
Adverse Event Reporting System. Nevertheless, vaccines have also been
associated with a host of chorioretinal pathologies beyond CSR. For
example, vaccinations against influenza, yellow fever, hepatitis B, and
Neisseria meningitidis have been associated with uveitis, acute idio
pathic
maculopathy,
acute
macular
neuroretinopathy,
Vogt-Koyanagi-Harada disease, and multiple evanescent white dot
syndrome.16–23
The pathophysiology of CSR remains incompletely understood, but
the current literature emphasizes the role of a hyperpermeable and
thickened choroid, as a result of hydrostatic forces, ischemia, or
inflammation.11 Further evidence suggests endogenous and exogenous
glucocorticoids contribute to the development of the choroidal vascul
opathy.24 The role of retinal pigment epithelium dysfunction remains
uncertain. Furthermore, CSR’s difficult to explain associations with
additional risk factors—systemic hypertension,25 alcohol use,25 gastro
esophageal reflux disease,26 and sympathomimetic agents27—offer
additional questions about the pathophysiology of disease.
There are several possible pathophysiologic mechanisms for the
mRNA vaccine to cause CSR. Our hypotheses for possible pathophysio
logic mechanisms are divided into three arms, related to increased
serum cortisol, free extracellular mRNA, and polyethlene glycol. First,
there is an association between CSR and high serum cortisol levels.28
The authors could not find any data related to serum cortisol levels after
mRNA immunizations. However in one study of a tetanus toxoid
vaccination, serum cortisol levels increased acutely nearly two-fold after
vaccination.29 Therefore, it seems reasonable that mRNA immunizations
may similarly trigger endogenous glucocorticoid release. On the other
hand, studies have consistently demonstrated that inflammatory cyto
kines inhibit glucocorticoid receptor expression through decreased re
ceptor translocation and binding affinity.30 Vaccines, including the
extensively studied influenza virus vaccine, induce mild inflammatory
responses.31–33 Another study showed that pain at injection site and
increased body temperature were accompanied by a pro-inflammatory
cytokine response.34
Other potential etiologies may arise from the presence of extracel
lular RNA. Extracellular naked RNA has been shown to increase the
permeability of endothelial cells and may thus contribute to leaky
choriocapillaris.35 Alternatively, extracellular naked RNA has been
shown to promote blood coagulation and thrombus formation.36 Studies
of CSR have highlighted that retinal areas with mid-phase inner
choroidal staining also have delayed choroidal filling, suggesting
choroidal lobular ischemia with associated areas of venous dilation.37,38
Interestingly, this phenomenon may explain the attenuated flow signal
in the choriocapillaris on OCTA in cases of CSR, including our case.7–9
Further, elevated serum plasminogen activator inhibitor-1, a fibrino
lytic, in CSR have led to the suggestion of a thrombotic mechanism for
these vascular changes.39
Finally, polyethylene glycol (PEG)-2000 is a lipid ingredient in the
vaccine formulation meant to enable the delivery of RNA into host cells.
PEGs are the most commonly used hydrophilic polymers used in drug
delivery tasked to control pharmacokinetic properties and deliver drug
to specific sites. Anaphylactic reactions have been reported in relation to
PEG compounds, that are used in bowel preparation regimens and pre
scription medications (e.g. methylprednisolone acetate).40 In addition,
subretinal PEG-8 induces choroidal neovascularization and choroidal
vessel thickening through activation of the complement pathway in
murine models.41,42

4. Conclusions
Acute CSR may be temporally associated with mRNA Covid-19
immunization.
Patient consent
Informed consent was obtained on this patient at the Instituto “La
Raza,” Mexico City, Mexico.
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